Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Case Report
Case Series
Current Issue
Editorial
Images/Videos in Hematology
Original Article
Original Research
Residents’ Corner
Systematic Reviews
What the Expert Says
View/Download PDF

Translate this page into:

Editorial
2 (
2
); 23-23
doi:
10.25259/JHAS_29_2022

“Precision medicine” in hematology

Department of Hematology, N.R.S. Medical College and Hospital, Kolkata, West Bengal, India
Corresponding author: Prakas Kumar Mandal, Department of Hematology, N.R.S. Medical College and Hospital, Kolkata, West Bengal, India. pkm.hem@gmail.com
Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Mandal PK. “Precision medicine” in hematology. J Hematol Allied Sci 2022;2:23.

Hematological diseases are a heterogeneous group of disorders originating from the hematopoietic stem cells with diverse etiology, pathogenesis, and prognosis. During the past decades, they have been studied by microscopy, clinical chemistry, immunophenotyping, conventional cytogenetics, polymerase chain reaction, different high-throughput technologies including next-generation sequencing (NGS), digitalized imaging, and so on. Systemic application of these techniques has permitted more precise and reproducible diagnoses,[1] risk stratification, and tailored therapeutic strategies.

Until recently, hematological malignancies are treated with highly cytotoxic drugs, radiation, and/or hematopoietic stem cell transplantation with many short-term and long-term side effects. Moreover, despite the improved response and survival rates, drug resistance and relapse remain major problems.

“Precision medicine” is a revolution in health-care systems encompassing optimal diagnosis, prognostication, and therapy decisions in an “individualized” manner.[2] “Precision medicine” in hematology employs disease-specific and patient-related issues to facilitate management of different hematological disorders. NGS not only allows to sequence the whole exome of the leukemic or lymphoma cells to search for gene expression profiles from the blood but also helps in therapeutic decision-making to effect so-called “precision medicine.” Targeting different mutations (BCR/ABL1, PML/RARA, and NPM/ALK) have therapeutic advantage over convention chemotherapy in diseases such as – CML, APL, and ALK +ve lymphomas, maximizing benefit while limiting toxicity.

Increasing knowledge of clinical genomics has accelerated the routine care of patients suffering from different benign and malignant hematological disorders.[3] However, the clinicians must carefully consider the ethical issues, especially those related to the uncertainty of the results of genomic testing in many cases.

References

  1. , . Introductory chapter: Hematology in times of precision and innovation In: , , eds. Hematology Latest Research and Clinical Advances. Available from: https://www.intechopen.com/chapters/61174 [Last accessed on 2022 Oct 14] London: IntechOpen; .
    [CrossRef] [Google Scholar]
  2. , . How “precise” is precision medicine in hematology? Haematologica. 2017;102:4-6.
    [CrossRef] [PubMed] [Google Scholar]
  3. , . Ethical considerations in genomic testing for hematologic disorders. Blood. 2017;130:460-5.
    [CrossRef] [PubMed] [Google Scholar]

Fulltext Views
650

PDF downloads
11
View/Download PDF
Download Citations
BibTeX
RIS
Show Sections